Assoc. Prof. Dr. Hany Fayed | Pharmacology | Best Researcher Award
Assoc. Prof. Dr. Hany Fayed | Pharmacology – Associate professor at National Research Centre, Egypt
Dr. Hany Moawad Ali Fayed is an Associate Professor of Pharmacology and Toxicology at the Medical Research and Clinical Studies Institute, National Research Centre (NRC), Egypt. With a remarkable academic background and over a decade of research experience, Dr. Fayed is widely recognized for his groundbreaking work in the fields of pharmacology and toxicology, especially in the study of liver diseases and hepatotoxicity. His research has contributed extensively to understanding the therapeutic potential of various compounds in treating liver fibrosis and related disorders, leading to significant advancements in both academic and clinical settings. Throughout his career, he has demonstrated a keen ability to integrate teaching with research, mentoring students while simultaneously pushing forward innovative scientific research. His publications and contributions to major international journals showcase his dedication to advancing pharmacological and toxicological knowledge.
Profile Verified:
Orcid | Google Scholar
Education:
Dr. Fayed’s academic journey began with a Bachelor of Veterinary Medical Sciences from Menofiya University, Egypt, where he graduated with distinction in 2007. He then pursued a Master’s degree in Veterinary Pharmacology at Cairo University, where he developed a keen interest in hepatoprotection and toxicology, culminating in his thesis on the hepatoprotective effects of artichoke extract against hepatocellular carcinoma in rats. His pursuit of excellence led him to a Ph.D. in Veterinary Pharmacology from Cairo University in 2017, where his dissertation focused on the evaluation of osteopontin in liver fibrosis, a study that significantly advanced the understanding of liver fibrosis mechanisms. Dr. Fayed’s robust educational background laid a solid foundation for his continued work in pharmacology and toxicology, making him a recognized expert in the field.
Experience:
Dr. Fayed’s professional experience spans over a decade, during which he has held pivotal positions in academia and research. From 2012 to 2022, he contributed as an educator at Cairo University, teaching pharmacological and toxicological experiments to veterinary students. This role allowed him to merge his passion for research with his dedication to training future scientists. Since 2015, Dr. Fayed has served as a researcher at the Medical Research and Clinical Studies Institute at NRC, progressing to an Associate Professor in 2023. Throughout his tenure at NRC, he has led various high-impact research projects and contributed to advancing pharmacological therapies, particularly in liver diseases and fibrosis. His involvement in both independent and collaborative research efforts has led to significant findings, reinforcing his position as a leader in his field.
Research Interest:
Dr. Fayed’s primary research interests are centered around pharmacology, toxicology, and liver diseases, with a focus on liver fibrosis, hepatotoxicity, and the molecular mechanisms of pharmacological agents. His recent research includes exploring the therapeutic effects of Canagliflozin and Linagliptin in liver carcinogenesis and the role of natural products in mitigating liver damage. He is also deeply involved in investigating the signaling pathways involved in liver fibrosis, such as AMPK/YAP/TAZ, IL-6/STAT3, and NRF2/HO-1, and their potential as therapeutic targets. His work on natural products, like Sansevieria species, also underscores his commitment to exploring alternative therapies for liver protection. Dr. Fayed’s interdisciplinary research is shaping the future of pharmacology and toxicology, providing essential insights into the treatment of liver diseases.
Award:
Dr. Fayed’s academic and professional excellence has not gone unnoticed. He was honored with the prestigious National Research Centre Prize for the Best Ph.D. Thesis in the Medical Division in 2017-2018. This recognition is a testament to his exceptional research contributions to the field of pharmacology and toxicology, particularly in the study of liver fibrosis. Additionally, Dr. Fayed’s continued success in securing research grants and leading innovative projects reflects his sustained contribution to scientific advancement. His recognition by both national and international bodies highlights his reputation as a highly respected researcher in the field.
Publications:
Dr. Fayed has an extensive publication record in reputable scientific journals. Notable publications include:
-
“Hepatoprotective Effect of Artichoke Extract Against Pre-cancerous Lesions of Hepatocellular Carcinoma in Rats” (2014), Life Science Journal.
This study explored the protective effects of artichoke extract against liver cancer, contributing to the growing body of research on natural hepatoprotective agents. 📚 -
“Molecular Mechanisms Underlying Hepatoprotective Effects of Artichoke Extract” (2014), World Journal of Pharmacy and Pharmaceutical Sciences.
This paper delves into the biochemical pathways through which artichoke extract modulates liver damage, establishing it as a key area for further research. 🌱 -
“Mesalazine: The Potential Prophylactic and Remedial Roles in Induced Liver Fibrosis in Rats” (2018), Chemico-Biological Interactions.
This publication highlighted the therapeutic potential of Mesalazine in treating liver fibrosis, demonstrating its role in combating liver damage. 🧪 -
“Targeting AngII/AT1R Signaling Pathway by Perindopril Inhibits Ongoing Liver Fibrosis in Rat” (2019), Journal of Tissue Engineering and Regenerative Medicine.
This research provided insights into the pharmacological mechanisms of Perindopril in mitigating liver fibrosis, showing its clinical potential. 💊 -
“Metabolomic Profiling of Sansevieria trifasciata and Hepatoprotective Effect in Liver Fibrosis” (2021), Egyptian Journal of Chemistry.
This study explored the hepatoprotective effects of Sansevieria species and their biochemical properties, offering new avenues for natural liver therapies. 🌿 -
“Rosuvastatin Restrains Liver Fibrosis: Involvement of NF-κB and Nrf2/HO-1 Pathways” (2022), International Journal of Veterinary Science.
This publication investigated the therapeutic potential of Rosuvastatin in treating liver fibrosis, contributing to the understanding of its molecular mechanisms. 🧬 -
“Erythropoietin Suppresses Hepatic Fibrosis Caused by Thioacetamide: Role of PI3K/Akt and TLR4 Signaling Pathways” (2023), Oxidative Medicine and Cellular Longevity.
This paper presented novel insights into the use of Erythropoietin for treating hepatic fibrosis, particularly in relation to key cellular signaling pathways. 🔬
Conclusion:
Dr. Hany Moawad Ali Fayed’s contributions to pharmacology and toxicology, particularly in liver disease research, demonstrate his unwavering commitment to advancing science. His work has provided critical insights into the molecular mechanisms behind liver fibrosis and hepatotoxicity, making him a leading figure in the field. Through his numerous publications, award-winning research, and dedication to teaching and mentoring, Dr. Fayed continues to shape the future of pharmacological sciences. His achievements are a testament to his expertise and passion for research, positioning him as an outstanding candidate for the “Best Researcher Award.”